首页 > 最新文献

American Journal of Medicine最新文献

英文 中文
Managing Energy, and Shaping Care: Insights from Adults with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through Co-Production Workshops.
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-15 DOI: 10.1016/j.amjmed.2025.02.008
Eleanor J Thornton, Lawrence D Hayes, Dawn S Goodwin, Nicholas Sculthorpe, Yeliz Prior, Nilihan E M Sanal-Hayes

Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, debilitating condition characterised by severe fatigue that is not relieved by rest and is often exacerbated by physical or mental activity. A key challenge for individuals with ME/CFS is energy management and to date, the only recommended strategy is "activity pacing." This approach involves balancing activity and rest to avoid overexertion and minimise the risk of symptom exacerbation, commonly known as "post-exertional malaise"(PEM). A recent systematic review highlighted significant shortcomings in activity pacing interventions for ME/CFS, noting that they lacked rigour, were brief, and did not follow guidelines or integrate recommended technology, limiting their relevance for modern energy management. To address these gaps, the present study aimed to explore ME/CFS patients' and health practitioners' perspectives on approaches to energy management, how their understanding of energy management has evolved over time, and their recommendations for future interventions concerning energy management.

Method: Eight individuals with ME/CFS participated in six one-hour long online co-production workshops with two researchers, with the option to provide input through written responses. Additionally, three health practitioners shared their perspectives via email. Thematic analysis of the data identified several key recommendations for improving ME/CFS care.

Results and conclusions: Workshops highlighted the need for early support, healthcare provider training, and public education to combat stigma and misconceptions around ME/CFS. Participants emphasised patient collaboration, research-informed practices, rigorous research, multidisciplinary teams, and the integration of technologies like mHealth, along with a comprehensive approach including sleep, diet, and psychological support for better symptom management and activity pacing.

{"title":"Managing Energy, and Shaping Care: Insights from Adults with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through Co-Production Workshops.","authors":"Eleanor J Thornton, Lawrence D Hayes, Dawn S Goodwin, Nicholas Sculthorpe, Yeliz Prior, Nilihan E M Sanal-Hayes","doi":"10.1016/j.amjmed.2025.02.008","DOIUrl":"https://doi.org/10.1016/j.amjmed.2025.02.008","url":null,"abstract":"<p><strong>Background: </strong>Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, debilitating condition characterised by severe fatigue that is not relieved by rest and is often exacerbated by physical or mental activity. A key challenge for individuals with ME/CFS is energy management and to date, the only recommended strategy is \"activity pacing.\" This approach involves balancing activity and rest to avoid overexertion and minimise the risk of symptom exacerbation, commonly known as \"post-exertional malaise\"(PEM). A recent systematic review highlighted significant shortcomings in activity pacing interventions for ME/CFS, noting that they lacked rigour, were brief, and did not follow guidelines or integrate recommended technology, limiting their relevance for modern energy management. To address these gaps, the present study aimed to explore ME/CFS patients' and health practitioners' perspectives on approaches to energy management, how their understanding of energy management has evolved over time, and their recommendations for future interventions concerning energy management.</p><p><strong>Method: </strong>Eight individuals with ME/CFS participated in six one-hour long online co-production workshops with two researchers, with the option to provide input through written responses. Additionally, three health practitioners shared their perspectives via email. Thematic analysis of the data identified several key recommendations for improving ME/CFS care.</p><p><strong>Results and conclusions: </strong>Workshops highlighted the need for early support, healthcare provider training, and public education to combat stigma and misconceptions around ME/CFS. Participants emphasised patient collaboration, research-informed practices, rigorous research, multidisciplinary teams, and the integration of technologies like mHealth, along with a comprehensive approach including sleep, diet, and psychological support for better symptom management and activity pacing.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium Glucose Cotransporter 2 inhibitors in Patients with Amyloidosis With or Without Heart Failure.
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-15 DOI: 10.1016/j.amjmed.2025.02.010
Silvio N Augusto, Rochell Issa, Simon Vanhentenrijk, David Kaelber, W H Wilson Tang

Background: Emerging evidence suggests sodium-glucose cotransporter 2 inhibitors (SGLT2i) benefits may extend to patients with amyloid cardiomyopathy, including transthyretin and amyloid light-chain amyloidosis subtypes. This study explores the broader implications of SGLT2i therapy across the spectrum of amyloidosis.

Methods: This retrospective cohort study used de-identified electronic health records from the TriNetX platform, encompassing data from 101 healthcare organizations between 2009 and 2024. Two cohorts of amyloidosis patients with heart failure were compared based on SGLT2i use. One cohort without a diagnosis of heart failure was also tested. Propensity score matching was applied to balance baseline characteristics. The primary outcome was all-cause mortality, and secondary outcomes included acute heart failure, acute myocardial infarction, stroke, and chronic kidney disease.

Results: The matched cohorts included 5,612 patients, with a mean age of 74 years and 64% male. SGLT2i-treated patients exhibited a higher 5-year survival probability (62.6%) compared to non-SGLT2i patients (39.1%) (HR 0.54, 95% CI 0.50-0.59; p<0.001). In amyloidosis patients without heart failure (n=1,490), SGLT2i therapy was associated with a significant reduction in all-cause mortality (HR 0.57, 95% CI 0.43-0.74; p <0.001). Sub-cohorts of transthyretin and amyloid light-chain amyloidosis in heart failure patients demonstrated consistent benefits with reduced mortality and favorable trends for acute myocardial infarction and stroke.

Conclusion: SGLT2i therapy is associated with significant survival benefits in amyloidosis patients with HF and may offer broader advantages across the amyloidosis spectrum, including amyloid patients without heart failure.

{"title":"Sodium Glucose Cotransporter 2 inhibitors in Patients with Amyloidosis With or Without Heart Failure.","authors":"Silvio N Augusto, Rochell Issa, Simon Vanhentenrijk, David Kaelber, W H Wilson Tang","doi":"10.1016/j.amjmed.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.amjmed.2025.02.010","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence suggests sodium-glucose cotransporter 2 inhibitors (SGLT2i) benefits may extend to patients with amyloid cardiomyopathy, including transthyretin and amyloid light-chain amyloidosis subtypes. This study explores the broader implications of SGLT2i therapy across the spectrum of amyloidosis.</p><p><strong>Methods: </strong>This retrospective cohort study used de-identified electronic health records from the TriNetX platform, encompassing data from 101 healthcare organizations between 2009 and 2024. Two cohorts of amyloidosis patients with heart failure were compared based on SGLT2i use. One cohort without a diagnosis of heart failure was also tested. Propensity score matching was applied to balance baseline characteristics. The primary outcome was all-cause mortality, and secondary outcomes included acute heart failure, acute myocardial infarction, stroke, and chronic kidney disease.</p><p><strong>Results: </strong>The matched cohorts included 5,612 patients, with a mean age of 74 years and 64% male. SGLT2i-treated patients exhibited a higher 5-year survival probability (62.6%) compared to non-SGLT2i patients (39.1%) (HR 0.54, 95% CI 0.50-0.59; p<0.001). In amyloidosis patients without heart failure (n=1,490), SGLT2i therapy was associated with a significant reduction in all-cause mortality (HR 0.57, 95% CI 0.43-0.74; p <0.001). Sub-cohorts of transthyretin and amyloid light-chain amyloidosis in heart failure patients demonstrated consistent benefits with reduced mortality and favorable trends for acute myocardial infarction and stroke.</p><p><strong>Conclusion: </strong>SGLT2i therapy is associated with significant survival benefits in amyloidosis patients with HF and may offer broader advantages across the amyloidosis spectrum, including amyloid patients without heart failure.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Revolution in Medicine and Surgery has Begun.
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-14 DOI: 10.1016/j.amjmed.2025.02.012
Reynold Spector

In the last few years, the longevity of Americans has fallen for the first time in our history. Obesity has mushroomed, heart disease still kills approximately 600,000 Americans and stroke 150,000. This review will cover the 8 most important non-genetic risk factors for heart disease and stroke. Meanwhile, recent research has clarified the root cause of atherosclerosis. The approval of tirzepatide to treat obesity in November 2023 by the FDA turns out to have enormous implications for medicine and surgery and the food industry.

{"title":"A Revolution in Medicine and Surgery has Begun.","authors":"Reynold Spector","doi":"10.1016/j.amjmed.2025.02.012","DOIUrl":"https://doi.org/10.1016/j.amjmed.2025.02.012","url":null,"abstract":"<p><p>In the last few years, the longevity of Americans has fallen for the first time in our history. Obesity has mushroomed, heart disease still kills approximately 600,000 Americans and stroke 150,000. This review will cover the 8 most important non-genetic risk factors for heart disease and stroke. Meanwhile, recent research has clarified the root cause of atherosclerosis. The approval of tirzepatide to treat obesity in November 2023 by the FDA turns out to have enormous implications for medicine and surgery and the food industry.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accuracy of Preoperative Risk Assessment: Individuals versus Groups.
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-14 DOI: 10.1016/j.amjmed.2025.02.007
Ralph H Stern
{"title":"Accuracy of Preoperative Risk Assessment: Individuals versus Groups.","authors":"Ralph H Stern","doi":"10.1016/j.amjmed.2025.02.007","DOIUrl":"https://doi.org/10.1016/j.amjmed.2025.02.007","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis: Tricuspid Regurgitation. Next Steps.
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-13 DOI: 10.1016/j.amjmed.2025.02.006
Daniel M Gelfman

Valvular heart disease is a common problem seen by primary care providers (PCPs). Transcatheter techniques used in the treatment in valvular heart disease have evolved lowering the risk of intervention. This allows for safer valve repair or replacement. Successful transcatheter valvular intervention is truly incredible. These lower risk procedures are changing who and when to refer patients as intervention may be safer than the risk of waiting. This issue is most critical in isolated chronic tricuspid regurgitation, as these patients were often felt to be too high risk for tricuspid surgical intervention. Now there exist multiple transcatheter interventions that can benefit patients with tricuspid regurgitation and right ventricular failure. Many of these procedures are still undergoing study and yet it appears clear that patients receive benefit from intervention. In addition, many patients with chronic tricuspid regurgitation and right ventricular failure are no longer seen by cardiology. It is imperative that PCPs are aware of which patients could potentially benefit from tricuspid valve intervention for tricuspid regurgitation for optimal referral and treatment.

{"title":"Diagnosis: Tricuspid Regurgitation. Next Steps.","authors":"Daniel M Gelfman","doi":"10.1016/j.amjmed.2025.02.006","DOIUrl":"https://doi.org/10.1016/j.amjmed.2025.02.006","url":null,"abstract":"<p><p>Valvular heart disease is a common problem seen by primary care providers (PCPs). Transcatheter techniques used in the treatment in valvular heart disease have evolved lowering the risk of intervention. This allows for safer valve repair or replacement. Successful transcatheter valvular intervention is truly incredible. These lower risk procedures are changing who and when to refer patients as intervention may be safer than the risk of waiting. This issue is most critical in isolated chronic tricuspid regurgitation, as these patients were often felt to be too high risk for tricuspid surgical intervention. Now there exist multiple transcatheter interventions that can benefit patients with tricuspid regurgitation and right ventricular failure. Many of these procedures are still undergoing study and yet it appears clear that patients receive benefit from intervention. In addition, many patients with chronic tricuspid regurgitation and right ventricular failure are no longer seen by cardiology. It is imperative that PCPs are aware of which patients could potentially benefit from tricuspid valve intervention for tricuspid regurgitation for optimal referral and treatment.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Culinary Conundrum: Flagellate Erythema Unveiled.
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-12 DOI: 10.1016/j.amjmed.2025.02.002
Natalie Soliman, Madeline June, Taylor A Bullock, John Anthony
{"title":"A Culinary Conundrum: Flagellate Erythema Unveiled.","authors":"Natalie Soliman, Madeline June, Taylor A Bullock, John Anthony","doi":"10.1016/j.amjmed.2025.02.002","DOIUrl":"https://doi.org/10.1016/j.amjmed.2025.02.002","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Primary Care Physicians in the Loneliness Epidemic
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-11 DOI: 10.1016/j.amjmed.2024.05.018
Jean-Claude Guidi DO, Gautam Koipallil MD, Jonathan Slimovitch MD, John McCormick MD
{"title":"The Role of Primary Care Physicians in the Loneliness Epidemic","authors":"Jean-Claude Guidi DO,&nbsp;Gautam Koipallil MD,&nbsp;Jonathan Slimovitch MD,&nbsp;John McCormick MD","doi":"10.1016/j.amjmed.2024.05.018","DOIUrl":"10.1016/j.amjmed.2024.05.018","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":"138 3","pages":"Page e38"},"PeriodicalIF":2.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Reply
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-11 DOI: 10.1016/j.amjmed.2024.06.025
Di Pan DO, MS , Julia Graham MD , Monika M. Safford MD
{"title":"The Reply","authors":"Di Pan DO, MS ,&nbsp;Julia Graham MD ,&nbsp;Monika M. Safford MD","doi":"10.1016/j.amjmed.2024.06.025","DOIUrl":"10.1016/j.amjmed.2024.06.025","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":"138 3","pages":"Pages e39-e40"},"PeriodicalIF":2.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Reply
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-11 DOI: 10.1016/j.amjmed.2024.11.004
Rafael Y. Brzezinski MD, PhD, Asaf Wasserman MD, Ori Rogowski MD, PhD, Shlomo Berliner MD, PhD, Ori Argov MD
{"title":"The Reply","authors":"Rafael Y. Brzezinski MD, PhD,&nbsp;Asaf Wasserman MD,&nbsp;Ori Rogowski MD, PhD,&nbsp;Shlomo Berliner MD, PhD,&nbsp;Ori Argov MD","doi":"10.1016/j.amjmed.2024.11.004","DOIUrl":"10.1016/j.amjmed.2024.11.004","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":"138 3","pages":"Page e44"},"PeriodicalIF":2.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient–Physician Communication: From Sales Tactics to Reflective Listening
IF 2.5 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-11 DOI: 10.1016/j.amjmed.2024.11.003
Alain Braillon MD, PhD
{"title":"Patient–Physician Communication: From Sales Tactics to Reflective Listening","authors":"Alain Braillon MD, PhD","doi":"10.1016/j.amjmed.2024.11.003","DOIUrl":"10.1016/j.amjmed.2024.11.003","url":null,"abstract":"","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":"138 3","pages":"Page e47"},"PeriodicalIF":2.5,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143376831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American Journal of Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1